Sahajanand Medical Technologies Ltd

Tue 17/11/2026,15:57:2 | NSE : SMT

₹548.855.60 (1.03%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 545.00

Previous Close

₹ 543.25

Volume

715963

Mkt Cap ( ₹ Cr)

₹ 5578.88

High

₹ 565.00

Low

₹ 541.00

52 Week High

₹ 578.70

52 Week Low

₹ 346.65

Book Value Per Share

₹ 69.82

Dividend Yield

0.00

Face Value

₹ 1.00

What's Your Call?

Collective community sentiment on Sahajanand Medical Technologies Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

548.85

13

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

13

Option Chain

Analyzes market sentiment, predicts Sahajanand Medical Technologies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Nov 2026, 9:10PM Schedule of Analyst/Investor Meet
  • Sahajanand Medical - Analysts/Institutional Investor Meet/Con. Call Updates

    8 Nov 2026, 9:38AM Sahajanand Medical Technologies Limited has informed the Exchange about Transcript of Earnings Call for Q2 & H1FY27 Financial Results held on Thursday
  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    8 Nov 2026, 9:49AM Transcript of Earnings Call for Q2 & H1 FY27 Financial Results held on Thursday, November 05, 2026.
  • Sahajanand Medical - Press Release

    6 Nov 2026, 12:15PM Sahajanand Medical Technologies Limited has informed the Exchange regarding a press release dated November 06, 2026, titled ""Publication of Unaudited
  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    6 Nov 2026, 1:30AM As per SEBI(LODR) Regulations, 2015- submission of audio recording of Earnings call held on 05 November 2026
  • Sahajanand Medical - Appointment Of Secretarial Auditor Of The Company

    5 Nov 2026, 7:32PM The Board of Directors of the Company at it Meeting held today has approved appointment of M/s. Amit Jaste & Associates, Company Secretaries as Secret
  • Sahajanand Medical - Change in Auditors

    5 Nov 2026, 7:10PM Sahajanand Medical Technologies Limited has informed the Exchange regarding Change in Auditors of the company.
  • Sahajanand Medical - General Updates

    5 Nov 2026, 6:37PM Sahajanand Medical Technologies Limited has informed the Exchange about approval of Board of Directors of the Company for investment by wholly owned s
  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Acquisition

    5 Nov 2026, 6:06PM Dear Sir/Ma'am- The Board of Directors of the Company has approved investment by wholly owned subsidiary company in SNP Medical Corp.
  • Sahajanand Medical - Investor Presentation

    5 Nov 2026, 5:21PM Sahajanand Medical Technologies Limited has informed the Exchange about Investor Presentation
  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Investor Presentation

    5 Nov 2026, 5:21PM Dear Sir/Ma'am- please find enclosed Investor presentation for wider circulation to general public.
  • Sahajanand Medical - Outcome of Board Meeting

    5 Nov 2026, 5:05PM Sahajanand Medical Technologies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
  • Sahajanand Medical - Board Meeting Outcome for Outcome Of The Board Meeting Dated November 5, 2026

    5 Nov 2026, 5:17PM Outcome of the Board Meeting dated November 5, 2026
  • Sahajanand Medical - Results- Financial Results For The Quarter Ended 30 September 2026

    5 Nov 2026, 5:11PM Results- Unaudited financial Results for the period ended 30th September 2026
  • Sahajanand Medical - Credit Rating

    4 Nov 2026, 3:59PM Sahajanand Medical Technologies Limited has informed the Exchange about Credit Rating
  • Sahajanand Medical - Announcement Under Regulation 30 Of SEBI Listing Obligation And Disclosure Requirement) Regulations, 201

    4 Nov 2026, 5:05PM Announcement under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Credit Rating

    4 Nov 2026, 3:50PM Intimation of upgradation of Credit Rating under Regulation 30 of SEBI (LODR) Regulations, 2015
  • Sahajanand Medical - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Oct 2026, 6:32PM Sahajanand Medical Technologies Limited has informed the Exchange about Schedule of Earnings Conference call to discuss the Q2 & H1FY27 financial resu
  • Sahajanand Medical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Oct 2026, 6:26PM Intimation of schedule of Earning Call
  • Sahajanand Medical - Board Meeting Intimation for Consideration Of Unaudited Standalone And Consolidated Financial Results Fo

    26 Oct 2026, 5:58PM Sahajanand Medical Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia,
  • Sahajanand Medical - Action(s) initiated or orders passed

    24 Oct 2026, 12:17PM Sahajanand Medical Technologies Limited has informed the Exchange about summons received under section 70 of Central Goods and Service tax Act.
  • Sahajanand Medical - Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015\r\n

    24 Oct 2026, 12:04PM Dear Sir/Ma'am-\r\n\r\nplease find enclosed herewith Intimation under regulation 30 of SEBI(LODR) Regulations regarding summons issued under section 7
  • Sahajanand Medical has submitted to BSE the Shareholding Pattern for the Period Ended October 22, 2026

    24 Oct 2026, 7:00AM As of October 2026, 36.19% is owned by Indian Promoters, 60.35% by Public and 3.46% by Non Promoters-Non Public. <p align=justify> Institutional holds
  • Sahajanand Medical - Updates

    23 Oct 2026, 6:53PM Sahajanand Medical Technologies Limited has informed the Exchange regarding 'Intimation under Regulation 6(1) of the Securities and Exchange Board of
  • Sahajanand Medical - Intimation Under Regulation 6(1) Of The Securities And Exchange Board Of India (Listing Obligations And

    23 Oct 2026, 6:50PM Dear Sir/ Ma'am, \r\n\r\nPlease find the enclosed the intimation under regulation 6(1) of SEBI(Listing Obligations and Disclosure Requirements) Regula
  • Sahajanand Medical - Updates

    23 Oct 2026, 3:02PM Sahajanand Medical Technologies Limited has informed the Exchange regarding 'Intimation under Regulation 8(2) of the Securities and Exchange Board of
  • Sahajanand Medical - Updates

    23 Oct 2026, 2:58PM Sahajanand Medical Technologies Limited has informed the Exchange regarding 'Disclosure under Regulation 30(5) of SEBI (Listing Obligations and Disclo
  • Sahajanand Medical - Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider T

    23 Oct 2026, 2:49PM Intimation under Regulations 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
  • Sahajanand Medical - Disclosure Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations,

    23 Oct 2026, 2:42PM The details of Key Managerial Personnel under Regulations 30(5) of SEBI (LODR), 2015
  • Sahajanand Medical - Trading Window

    23 Oct 2026, 1:32PM Sahajanand Medical Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Sahajanand Medical Technologies Ltd. debuts with 6.99% premium at Rs 368.05

    23 Oct 2026, 10:00AM Sahajanand Medical Technologies Ltd. makes a strong debut on the bourses with scrip got listed at Rs 368.05 on the Bombay Stock Exchange, a 6.99 per c
  • Sahajanand Medical - Listing of Equity Shares of Sahajanand Medical Technologies Ltd

    23 Oct 2026, 7:58AM Trading Members of the Exchange are hereby informed that effective from October 23, 2026, the Equity Shares of Sahajanand Medical Technologies Ltd (Sc
  • Sahajanand Medical announces launch of initial public offering

    12 Oct 2026, 7:10PM Sahajanand Medical Technologies Ltd. has announced public offering of 13822116 shares at a price of Rs 1.00 each for Cash at a Premium of Rs 343.00 pe

Key fundamentals

Evaluate the intrinsic value of Sahajanand Medical Technologies Ltd stock 

Name March-26
Assets 877.8537
Liabilities 877.8537
Equity 9.8131
Gross Profit 77.9244
Net Profit 43.5022
Cash From Operating Activities 8.4261
NPM(%) 7.89
Revenue 551.196
Expenses 473.2716
ROE(%) 6.12

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Sahajanand Medical Technologies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 768.70 -1.31 15.26 313.55 -26.19 0.65
Lotus Eye Hospital and Institute Ltd 104.96 3.73 477.09 1142.55 0.39 0.00
Vaishali Pharma Ltd 7.18 2.28 18.41 7167.58 15.42 0.00
Astec Lifesciences Ltd 556.30 0.52 0.00 1224.18 -363.14 0.00

Company Info

Our Company was initially formed as a partnership firm named `M/s Sahajanand Vascular Technoventions' pursuant to a partnership deed dated October 25, 1999 between two partners namely, Sharada Dhirajlal Kotadia and Rajesh Laljibhai Vaishnav. Subsequently, pursuant to a partnership deed dated September 30, 2001, between Sharada Dhirajlal Kotadia, Rajesh Laljibhai Vaishnav, Dhirajlal Vallabhbhai Kotadia, Dhirajkumar Savjibhai Vasoya, Vinod Savjibhai Vasoya, Jitendra V. Kotadia and Nayna Dhirajkumar Vasoya (collectively, the "Partners"), the partnership firm was re-constituted, and the name of the partnership firm was changed to `M/s Sahajanand Medical Technologies'.The partnership firm was subsequently converted into a joint stock company and was registered as a private limited company named `Sahajanand Medical Technologies Private Limited' pursuant to a certificate of incorporation dated October 18, 2001, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli, in accordance with provisions of the Companies Act, 1956. Subsequently, our Company was converted into a public limited company as approved by a resolution of our Board dated March 10, 2021 and the special resolution dated April 27, 2021 passed by the Shareholders of our Company, following which the name of our Company was changed to `Sahajanand Medical Technologies Limited' and a fresh certificate of incorporation was issued by the RoC on May 7, 2021.Major Events and Milestones:2016- Samara Capital Markets Holding Limited invested around ? 400 million by subscribing to 9,406,419 Equity Shares of our Company. Additionally, Samara Capital Markets Holding Limited also purchased 9,406,419 Equity Shares of our Company from existing shareholders for a consideration around ? 400 million2017- Samara Capital Markets Holding Limited invested ? 700 million by subscribing to 13,717,421 Equity Shares of our Company- Enrolment of 1,435 patients completed for TALENT trial on the safety and efficacy of a sirolimus eluting coronary stent2018- NHPEA Sparkle Holding B.V. invested ? 1,600 million by subscribing to 16,396,803 Equity Shares of our Company2019- TALENT trial study for Supraflex presented by Professor Patrick Serruys and published in The Lancet- Received EC Certificate for full quality assurance system granted to Supraflex Cruz- Acquired Imex Salud S.L. to establish direct operations in Spain, for a sum of _ 2.55 million- Acquired 75% of the quotas of SMT Brazil (erstwhile Zarek Distribuidora De Produtos Hospitalares Eireli) to establish hybrid operations in Brazil, for a sum of R$ 18.82 million2020- Acquired VCL (as an erstwhile subsidiary of our Company) for a consideration of ? 687.29 million- Acquired Vascular Innovations, a wholly owned subsidiary of SMT Ireland, for a sum of ? 443.00 million2022- Publication of the safety and performance study of "Hydra TAVI" in JACC: Cardiovascular Interventions, demonstrating its efficacy in the treatment of symptomatic severe aortic stenosis2024- Launch of Hydra TAVI in Russia, Malaysia and Hungary- Completion of patient enrolment for TUXEDO-2, a clinical trial to evaluate the efficacy of drug eluting stent "Supraflex Cruz" in diabetic patients with multi vessel coronary artery disease- TGA Australia's approval for drug eluting stent "Supraflex Cruz"- Publication of S-FLEX UK-II Registry study on "Supraflex Cruz" demonstrating its clinical safety and performance in BMJ Open- Publication of the Compare 60/80 HBR trial study in Circulation: Cardiovascular Interventions demonstrating the efficacy of "Supraflex Cruz" in high bleeding risk patients2025- SMT Ireland, our wholly owned Subsidiary, purchased shares of the common stock of SNP Medical Corporation- Publication of 3 year follow up outcomes of the FIRE Trial of "Supraflex Cruz" in Jama Cardiology, demonstrating sustained clinical benefits of Supraflex Cruz in older patients (>75 years) with myocardial infarction and multivessel disease- Publication of 30 day and 6 months follow up outcomes of the GENESIS -II study of Hydra Transcatheter heart valve device in Asia Intervention and Euro PCR 2025, respectively, demonstrating its safety and performance in treating severe aortic stenosis in high risk patients- Presentation of the results of TUXEDO-2, multivessel TALENT trial and Cruz Senior Study, along with results of SFlex Netherlands Registry demonstrating the non inferiority, proven safety, efficacy, and consistent performance of the Supraflex Cruz across a broad spectrum of complex patient populations, at Transcatheter Cardiovascular Therapeutics 2025

Our Company was initially formed as a partnership firm named `M/s Sahajanand Vascular Technoventions' pursuant to a partnership deed dated October 25, 1999 between two partners namely, Sharada Dhirajlal Kotadia and Rajesh Laljibhai Vaishnav. Subsequently, pursuant to a partnership deed dated September 30, 2001, between Sharada Dhirajlal Kotadia, Rajesh Laljibhai Vaishnav, Dhirajlal Vallabhbhai Kotadia, Dhirajkumar Savjibhai Vasoya, Vinod Savjibhai Vasoya, Jitendra V. Kotadia and Nayna Dhirajkumar Vasoya (collectively, the "Partners"), the partnership firm was re-constituted, and the name of the partnership firm was changed to `M/s Sahajanand Medical Technologies'.The partnership firm was subsequently converted into a joint stock company and was registered as a private limited company named `Sahajanand Medical Technologies Private Limited' pursuant to a certificate of incorporation dated October 18, 2001, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli, in accordance with provisions of the Companies Act, 1956. Subsequently, our Company was converted into a public limited company as approved by a resolution of our Board dated March 10, 2021 and the special resolution dated April 27, 2021 passed by the Shareholders of our Company, following which the name of our Company was changed to `Sahajanand Medical Technologies Limited' and a fresh certificate of incorporation was issued by the RoC on May 7, 2021.Major Events and Milestones:2016- Samara Capital Markets Holding Limited invested around ? 400 million by subscribing to 9,406,419 Equity Shares of our Company. Additionally, Samara Capital Markets Holding Limited also purchased 9,406,419 Equity Shares of our Company from existing shareholders for a consideration around ? 400 million2017- Samara Capital Markets Holding Limited invested ? 700 million by subscribing to 13,717,421 Equity Shares of our Company- Enrolment of 1,435 patients completed for TALENT trial on the safety and efficacy of a sirolimus eluting coronary stent2018- NHPEA Sparkle Holding B.V. invested ? 1,600 million by subscribing to 16,396,803 Equity Shares of our Company2019- TALENT trial study for Supraflex presented by Professor Patrick Serruys and published in The Lancet- Received EC Certificate for full quality assurance system granted to Supraflex Cruz- Acquired Imex Salud S.L. to establish direct operations in Spain, for a sum of _ 2.55 million- Acquired 75% of the quotas of SMT Brazil (erstwhile Zarek Distribuidora De Produtos Hospitalares Eireli) to establish hybrid operations in Brazil, for a sum of R$ 18.82 million2020- Acquired VCL (as an erstwhile subsidiary of our Company) for a consideration of ? 687.29 million- Acquired Vascular Innovations, a wholly owned subsidiary of SMT Ireland, for a sum of ? 443.00 million2022- Publication of the safety and performance study of "Hydra TAVI" in JACC: Cardiovascular Interventions, demonstrating its efficacy in the treatment of symptomatic severe aortic stenosis2024- Launch of Hydra TAVI in Russia, Malaysia and Hungary- Completion of patient enrolment for TUXEDO-2, a clinical trial to evaluate the efficacy of drug eluting stent "Supraflex Cruz" in diabetic patients with multi vessel coronary artery disease- TGA Australia's approval for drug eluting stent "Supraflex Cruz"- Publication of S-FLEX UK-II Registry study on "Supraflex Cruz" demonstrating its clinical safety and performance in BMJ Open- Publication of the Compare 60/80 HBR trial study in Circulation: Cardiovascular Interventions demonstrating the efficacy of "Supraflex Cruz" in high bleeding risk patients2025- SMT Ireland, our wholly owned Subsidiary, purchased shares of the common stock of SNP Medical Corporation- Publication of 3 year follow up outcomes of the FIRE Trial of "Supraflex Cruz" in Jama Cardiology, demonstrating sustained clinical benefits of Supraflex Cruz in older patients (>75 years) with myocardial infarction and multivessel disease- Publication of 30 day and 6 months follow up outcomes of the GENESIS -II study of Hydra Transcatheter heart valve device in Asia Intervention and Euro PCR 2025, respectively, demonstrating its safety and performance in treating severe aortic stenosis in high risk patients- Presentation of the results of TUXEDO-2, multivessel TALENT trial and Cruz Senior Study, along with results of SFlex Netherlands Registry demonstrating the non inferiority, proven safety, efficacy, and consistent performance of the Supraflex Cruz across a broad spectrum of complex patient populations, at Transcatheter Cardiovascular Therapeutics 2025

Parent Organisation

Sahajanand Medical Technologies Ltd.

Founded

18/10/2001

Managing Director

Mr.Bhargav Dhirajlal Kotadia

NSE Symbol

SMTEQ

FAQ